Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
13,264,980
-
Total 13F shares
-
4,384,748
-
Share change
-
+1,071,973
-
Total reported value
-
$18,898,424
-
Put/Call ratio
-
9.3%
-
Price per share
-
$4.31
-
Number of holders
-
49
-
Value change
-
+$4,718,117
-
Number of buys
-
23
-
Number of sells
-
16
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q2 2025
As of 30 Jun 2025,
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) was held by
49 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,384,748 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., Eversept Partners, LP, JPMORGAN CHASE & CO, BlackRock, Inc., CITADEL ADVISORS LLC, Palo Alto Investors LP, BANK OF AMERICA CORP /DE/, and UBS Group AG.
This page lists
49
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.